<p>The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's <a href="https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative">Cancer Moonshot Initiative</a>. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study is one of the selected studies under this program. For this study, genomic characterization (WGS, WXS, Total RNAseq, miRNAseq) has been performed on cervical tumor tissue from patients with advanced disease (persistent, recurrent, and metastatic) and matching germline samples. It is hypothesized that the characterization of these tissues using next generation sequencing will lead to the identification of relevant novel genetic aberrations within the immunologic, DNA repair, and tumor angiogenesis domains that dichotomize the study population into exceptional responders and non-responders to systemic therapy, with a spectrum of response manifesting between the two extremes.</p>

MP2PRT: Genomic and Molecular Characterization of Biomarkers Associated    with Tumor Angiogenesis, DNA Repair, and Immunologic Tolerance using    Samples from the NRG Oncology Phase 3 Randomized Trial, GOG-0240    (NCT00803062)